Biofrontera AG: Biofrontera Expands belixos® Dermo-Cosmetics Product Line with belixos® To Go

Leverkusen (pta020/08.07.2016/14:00 UTC+2) Biofrontera Expands belixos® Dermo-Cosmetics Product Line with belixos® To Go

- Marks fifth product in consumer product line
- New product provides rapid, effective and targeted relief for itchiness, insect bites and burns
- Immediately available in Europe through pharmacies and Amazon

Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced the expansion of its belixos® dermatologic cosmetic product line with the market launch of belixos® To Go. belixos® To Go is the fifth product in the consumer product line and combines the benefits of the creme, liquid and gel products for a convenient, all-in-one solution on the go. The belixos® range is a collection of specialty cosmetics for problematic conditions such as itchy, inflamed and sun-damaged skin.

As with the other products in the belixos® skincare line, belixos® To Go combines traditional medicinal plant extracts with an innovative biocolloid formulation to provide rapid, effective and targeted relief for itchiness, insect bites and minor burns. belixos® To Go is packaged as a convenient and practical 5ml roll-on applicator with a stainless steel ball, offering a simple and hygienic application while creating an immediate cooling effect on the affected skin.

In belixos® To Go, the traditional medicinal plant Mahonia aquifolium is combined with sea mayweed to provide an anti-inflammatory and anti-bacterial effect, while alleviating painful stinging and itching. The Sepicalm S complex has a calming effect on the skin and expands the range of use of the new cosmetic product. This combination effectively enables skin inflammation and redness to subside quickly and allows the skin to regenerate. In addition, special galenic formulation ensures rapid permeation into the skin with no greasy residue.

"The launch of belixos® To Go expands our range of active cosmetics with a promising product for use in acute skin problems," commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera. "The size and practical form of application make belixos® To Go a convenient take-along for insect bites and emergencies such as minor burns."

The acute care product belixos® To Go, like all belixos® products, is available with immediate effect in Europe in pharmacies and online from Amazon.

In case of queries, please contact:

Contact for investors
Thomas Schaffer, Chief Financial Officer
press@biofrontera.com
Telephone: +49-214-87632-0
Fax: +49-214- 87632-90

Brainwell Asset Solutions
Jürgen Benker
+49-152-08931514

Contact for journalists
Cortent Kommunikation AG
Volker Siegert
volker.siegert@cortent.de
Telephone: +49-69-5770300-11

Background:
Biofrontera AG (FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug that was initially approved in Europe, and has now also received approval in the USA, for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval in Europe, and now in the USA as well, for a drug it has developed itself.

The company also markets the Belixos® dermatological range of cosmetics. The Belixos® products, comprising a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative treatment of chronic skin conditions such as neurodermatitis or psoriasis. Belixos® Protect, a regenerating daily care product for sun-damaged skin, complements this dermo-cosmetic line . All Belixos® products are available in Europe from Amazon and in pharmacies.

The Biofrontera Group was established in 1997 by Professor Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

http://www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor & public relations
Phone:	+49 (0) 214 87 63 20
E-Mail:	press@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE0006046113 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart